Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
805K
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
101K
-
Shares change
-
-14.9K
-
Total reported value, excl. options
-
$109K
-
Value change
-
-$124K
-
Number of buys
-
6
-
Number of sells
-
-3
-
Price
-
$1.08
Significant Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q1 2023
15 filings reported holding INM - InMed Pharmaceuticals Inc. - Common Shares, no par value as of Q1 2023.
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) has 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 101K shares
of 805K outstanding shares and own 12.54% of the company stock.
Largest 10 shareholders include RENAISSANCE TECHNOLOGIES LLC (77.5K shares), SUSQUEHANNA INTERNATIONAL GROUP, LLP (18.8K shares), UBS Group AG (2.62K shares), BANK OF AMERICA CORP /DE/ (1.82K shares), BlackRock Inc. (50 shares), ADVISOR GROUP HOLDINGS, INC. (41 shares), AllSquare Wealth Management LLC (21 shares), Federation des caisses Desjardins du Quebec (19 shares), NATIONAL BANK OF CANADA /FI/ (12 shares), and Advisory Services Network, LLC (6 shares).
This table shows the top 11 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.